RxDoctor Payments Data

Claudio Gallego, MD

Nephrology · San Dimas, CANPI 1285649962

Payments from drug & device makers

$1,639in general payments, 2019–2025

Across 52 payments — averaging $31.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$311
  • Aurinia Pharma U.S., Inc.$247
  • Calliditas Therapeutics US Inc.$217
  • Amgen$211
  • Fresenius USA Marketing, Inc.$105
  • GSK$94
  • plus $454 from 11 others

What the payments were for

  • Speaking & faculty fees$493%
  • Food & beverage$1,45489%
  • Education$1368%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,639 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$334,581
Medicare patients
341
Services billed
2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol157$149,547
XphozahTenapanor Hcl34$102,391
LokelmaSodium Zirconium Cyclosilicate159$85,208
VelphoroSucroferric Oxyhydroxide21$57,353
Sevelamer Hcl75$49,895
EliquisApixaban65$39,683
JanuviaSitagliptin Phosphate31$34,956
OzempicSemaglutide32$27,814
Sevelamer Carbonate154$27,061
Lanthanum Carbonate23$23,635
KerendiaFinerenone16$22,787
Clonidine218$19,211
JardianceEmpagliflozin24$18,508
Cinacalcet Hcl16$17,481
Calcium Acetate333$16,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$57$234,756316 claims
Fresenius USA Marketing, Inc.Velphoro$105$57,35321 claims
Novo NordiskOzempic$19$27,81432 claims
BayerKerendia$67$22,78716 claims
Boehringer IngelheimJardiance$24$18,50824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in San Dimas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →